Product Information
CTLA-4 is a protein that regulates the immune response. The CTLA-4 - inhibitor (CTLA-4I) binds to CTLA-4 and blocks its interaction with immune cells, leading to an increase in the number of T cells. This drug has been shown to be effective against urothelial carcinoma and autoimmune diseases. It also has been used in some cases of angiosarcoma, toxic epidermal necrolysis, renal cell cancer, and other cancers. CTLA-4I is most often used in combination with platinum-based chemotherapy or radiation therapy. There are multicenter phase II clinical trials underway for this drug for use as a treatment for hematopoietic malignancies such as leukemia and lymphoma.
Chemical properties
Technical inquiry about: 3D-FC137667 CTLA-4 - inhibitor
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
